Compounded GLP-1s when insurance says no: what's real

What did @wellnessnursecourtnay actually say?

The claim is simple and direct: if your doctor won't prescribe a GLP-1 or your insurance won't cover it, a compounded telehealth route can still get you access. The caption frames it as a workaround, and the video's three-word punchline, "Here you go," is pretty clearly an advertisement dressed as reassurance.

To be fair, the creator doesn't make outrageous medical claims. There's no promise of a cure, no dosing advice, no suggestion that compounded semaglutide is identical to Wegovy. The pitch is about access, not pharmacology. That's a narrower claim than we usually see in this space, and narrower claims are easier to evaluate honestly.

Still, the framing that a doctor saying no is just a bureaucratic obstacle you can route around deserves scrutiny. A physician declining to prescribe a GLP-1 isn't always wrong. Sometimes it's the right call.

Does the science back this up?

The access problem is real. The workaround is real. But the science on compounded GLP-1s is genuinely complicated, and glossing over that does patients a disservice.

GLP-1 receptor agonists like semaglutide have strong clinical evidence behind them. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced around 15% body weight reduction over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% weight loss. The drugs work. That part isn't in dispute.

What is in dispute is whether compounded versions deliver the same product. The FDA has repeatedly warned that compounded semaglutide is not FDA-approved and has not been evaluated for safety or efficacy. In 2024, the FDA noted it had received hundreds of adverse event reports tied to compounded semaglutide, some involving dosing errors linked to concentration variability. A telehealth prescription from a licensed provider offers a real clinical interaction, which matters. But the medication at the end of that chain carries more uncertainty than the branded version.

What did they get wrong (or right)?

They got the access problem right. Insurance coverage for GLP-1s remains inconsistent and often exclusionary. A 2023 KFF analysis found that fewer than 25% of large employer health plans covered anti-obesity medications, and prior authorization denial rates for GLP-1s are high. The frustration the creator names is legitimate and well-documented.

What the video skips, and this matters, is why a doctor might say no beyond just being unhelpful. GLP-1s are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (FDA labeling, 2021). They carry real gastrointestinal side effects. Pancreatitis has been reported. A physician declining to prescribe isn't automatically an obstacle. Sometimes it's risk stratification.

The video also doesn't tell viewers that compounded GLP-1s are not equivalent to brand-name drugs. That's not a technicality. It's a safety distinction the FDA has gone out of its way to make explicit. A telehealth consult with a licensed provider is a legitimate path for many people, but the compound at the end of that path deserves honest framing.

What should you actually know?

If you've been denied a GLP-1 by your doctor or insurer, telehealth platforms with licensed prescribers are a legal and sometimes appropriate option for many patients. But go in with realistic expectations and honest information, not just a workaround mentality.

First, understand that compounded semaglutide or tirzepatide is not the same as Ozempic or Wegovy. The active ingredient may be similar, but manufacturing standards, excipients, and concentration accuracy differ. The FDA has explicitly stated compounded versions have not been proven safe or effective (FDA, 2023).

Second, a telehealth consult should function like a real clinical evaluation. A good provider will ask about your thyroid history, your cardiovascular risk, your current medications, and whether GLP-1 therapy is actually appropriate for you. If the consultation feels like a rubber stamp, that's a warning sign.

Third, the evidence base for GLP-1s in obesity and type 2 diabetes is strong. Davies et al. (2021, Diabetes Care) confirmed cardiovascular benefits for semaglutide in high-risk patients. These are real medicines with real benefits and real risks, not wellness supplements.

• Insurance denial is common and often arbitrary, but a physician's clinical refusal may have legitimate medical reasons behind it.
• Compounded GLP-1s are not FDA-approved and carry documented risks around dosing accuracy.
• Telehealth prescribers can be legitimate providers, but evaluate the quality of the consultation, not just the access it offers.